Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Abiomed Announces Several Reimbursement Milestones



Abiomed Announces Several Reimbursement Milestones

  * Four Commercial Insurers Institute Broad Impella Coverage
  * Impella Economic Study Published in The Journal of Managed Care Medicine
    (JMCM)

DANVERS, Mass., March 4, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD),
a leading provider of breakthrough heart support technologies, today provided
a reimbursement update. Abiomed announced several recent Impella coverage
decisions from national payers including Humana, UnitedHealthcare,
Independence Blue Cross and Capital BlueCross. The recently updated coverage
decisions include new Impella policies in the payers' commercial and/or
Medicare Advantage plans.

Additionally, an economic study on the use of percutaneous ventricular assist
devices (pVAD) was published in the February edition of The Journal of Managed
Care Medicine (JMCM), "A Budget Impact Model to Estimate the Cost Dynamics of
Treating High-Risk Heart Failure Patients with Advanced Percutaneous Cardiac
Assist Devices: The Payer Perspective."

The study developed a Budget Impact Model (BIM) to estimate the annual direct
medical costs of treatment and the combined incremental budget impact of
introducing a pVAD treatment option. A BIM is a standard approach used by most
commercial payers today to assess impact on their spend per member. The study
concluded that the per-member per-month (PMPM) impact of the use of pVADS in
very challenging patient populations was minimal throughout the technology
adoption curve and that patients did not require expensive readmissions for
hospital care.

"In this era of healthcare reform, these models help identify the most
effective and efficient ways to manage patients, particularly patients with
the potential to generate significant costs if not managed properly," said
David Gregory, MPA, FACHE, author of the study and Executive Vice President
and Partner, Presscott Associates - A Division of ParenteBeard, LLC.

"New clinical guidelines, coupled with clinical and economic studies like
this, are all paving the way for Impella to become the new standard of care,"
said Michael R. Minogue, Chairman, President and Chief Executive Officer of
Abiomed

Data for this study were obtained from a nationally-recognized database
compiled by OptumInsight, Inc. (Eden Prairie, MN) comprising claims generated
by a national commercial health plan consisting of approximately 25 million
members. This model tracked patients for a full year subsequent to the initial
hospital stay.

The Journal of Managed Care Medicine (JMCM) is the official publication of
National Association of Managed Care Physicians (NAMCP). The mission of NAMCP
is to improve patient outcomes by providing educational material,
evidence-based tools and resources to medical directors from purchasers, plans
and provider systems. The JMCM article can be viewed online at:
http://www.namcp.org/journals/jmcm/articles/16-1/budget_impact.pdf

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support. Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com

The Abiomed logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13564

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently filed
Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.

CONTACT: Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         978-646-1590
         slisa@abiomed.com
        
         Aimee Genzler
         Corporate Communications Manager
         978-646-1553
         ir@abiomed.com

Abiomed Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement